drugset / Trial / NCT05298995
GD2-CAR T Cells for Pediatric Brain Tumours
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety and efficacy of iC9-GD2-CAR T-cells, a third generation (4.1BB-CD28) CAR T cell treatment targeting GD2 in paediatric or young adult patients affected by relapsed/refractory malignant central nervous system (CNS) tumors. In order to improve the safety of the approach, the suicide gene inducible Caspase 9 (iC9) has been included.
Timeline
- Start
- 2023-11-09
- Primary completion
- 2027-11
- Completion
- 2038-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GD2-CART01 | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | GD2-CART01 | Cell therapy | 6e+06 cells/kg | Intravenous |